Top News

Jul 20, 2016
Thirty percent of current Remicade patients could be eligible for a switch to competitors such as Inflectra, according to estimates, although J&J doubts this will occur in the United States in 2016.
Jul 19, 2016
By BioPharm International Editors
The company received prequalification for its Prevenar 13 MDV, which allows global use of the vaccine by United Nations countries and agencies.
Jul 12, 2016
By BioPharm International Editors
EAG Laboratories announces new company identity and intent to expand testing, analysis, and characterization capabilities across multiple markets.
Jul 11, 2016
FDA reviewers have found that Sandoz's GP2015, a biosimilar version of Amgen's Enbrel, is highly similar to the original product in terms of purity, safety, and potency.
Jul 11, 2016
By BioPharm International Editors
Patheon launches initial public offering to repay outstanding notes and expenses.
Jul 08, 2016
A Federal Circuit court ruled biosimilar makers must wait 180 days after receiving FDA approval before bringing drugs to market.
Jul 06, 2016
By BioPharm International Editors
The agency says, for now, it’s business as usual.
Jul 05, 2016
By BioPharm International Editors
The acquisition will give Bristol-Myers Squibb full rights to Cormorant’s HuMax-IL8 antibody program.
Jun 28, 2016
Antibodies to dengue may either confer protective immunity to the Zika virus or enhance disease severity in secondary, related infections such as Zika.
Jun 27, 2016
By BioPharm International Editors
The companies agree to exchange ownership of Sanofi’s animal health and Boehringer Ingelheim’s consumer healthcare businesses.
native1_300x100
lorem ipsum